North Carolina

Global health R&D delivers for North Carolina

Click here to select a new state

Select a new state

US government investment in global health R&D has delivered

$2.4 billion

to North Carolina research institutions

35,500+ new jobs

for North Carolina

North Carolina's top USG-funded global health R&D institutions

Duke University

$994.5 million

FHI 360 (previously Family Health International)

$606.2 million

PPD (Pharmaceutical Product Development)

$304 million

University of North Carolina at Chapel Hill (including the Carolina Vaccine Institute)

$288.7 million

Rho Inc.

$45.3 million

RTI International (Research Triangle Institute)

$38.5 million

BioCryst Pharmaceuticals Inc.

$31.3 million

Undisclosed NC-based industry recipients

$27.8 million

Qorvo Inc.

$26.3 million

Mucommune LLC

$8.9 million

North Carolina State University Raleigh

$7.6 million

Advanced Liquid Logic*

$4.6 million

Affinergy LLC

$4.1 million

Redbud Labs Inc.

$4.1 million

Eppin Pharma Inc.

$3.7 million

Wake Forest University

$3.6 million

Attagene Inc.

$3.2 million

Baebies

$2.8 million

GREER Laboratories (including Allermed Laboratories)

$2.5 million

Medicago USA*

$2.4 million

Global Vaccines Inc.*

$2.2 million

Collaborations Pharmaceuticals Inc.

$2.1 million

Alderon Biosciences Inc.*

$2 million

Atom Bioworks

$1.8 million

NIRvana Sciences Inc.

$1.8 million

Novan Inc.

$1.5 million

Burleson Research Technologies

$1.1 million

Appalachian State University

$997 thousand

East Carolina University

$896 thousand

AccuGenomics

$810 thousand

University of North Carolina at Greensboro

$748 thousand

Calla Health Foundation

$682 thousand

Boragen

$663 thousand

Jericho Sciences LLC

$508 thousand

North Carolina Central University

$476 thousand

Diabetic Health Inc. (formerly Clinical Sensors Inc.)

$371 thousand

Base4 Biotechnology (formerly Nymirum)

$349 thousand

Triangle Biotechnology

$340 thousand

Mycosynthetix Inc.

$325 thousand

AimMax Therapeutics Inc.

$307 thousand

Eldec Pharmaceuticals Inc.

$300 thousand

OncoTrap, Inc.

$299 thousand

Adámas Nanotechnologies

$285 thousand

Indexus Biomedical LLC

$278 thousand

Gradient Medical

$273 thousand

Ribometrix LLC

$268 thousand

Global Bridge Pharmaceutical Inc.

$122 thousand

Parexel

$92 thousand

Natural Products and Glycotechnology Research Institute*

$75 thousand

SDV Office Systems

$67 thousand

North Carolina's top areas of global health R&D by USG funding

20.1%

COVID-19

3.1%

Flioviral diseases (including Ebola, Marburg)

61.1%

HIV/AIDS

3.5%

Malaria

2.9%

Reproductive health

2.5%

Tuberculosis

6.7%

Other

Arenaviral hemorrhagic fevers (including Lassa fever)

Bacterial pneumonia & meningitis

Bunyaviral diseases (including CCHF, RVF, SFTS)

Chikungunya

Cryptococcal meningitis

Dengue

Diarrheal diseases

Emergent non-polio enteroviruses (including EV71, D68)

Helminth infections (worms & flukes)

Henipaviral diseases (including Nipah)

Hepatitis B

Hepatitis C

Histoplasmosis

Kinetoplastids

Multi-disease/health area R&D

Other coronaviruses (including MERS, SARS)

Salmonella infections

Snakebite envenoming

Zika

Neglected and emerging diseases in North Carolina

Chikungunya cases

Dengue cases

152

HIV diagnoses

4408

Malaria cases

781

Mpox cases

244

Tuberculosis cases

2409

Viral hemorrhagic fevers cases

Global health R&D at work in North Carolina

RTI International, in partnership with TB Alliance, is supporting the development of new drugs for tuberculosis (TB). RTI helped the alliance bring to market a groundbreaking new drug for highly drug-resistant TB. The drug is part of a combination regimen that has reduced treatment time from up to two years to six months while dramatically improving outcomes. The regimen has a 90 percent treatment success rate, compared to prior treatments that were about 50 percent successful. This lifesaving drug is an important new tool in combatting drug-resistant TB both globally and in the United States.

Footnotes

Methodology
US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
*Organization appears to be closed/out of business.
Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
Case study photo: Flickr/Victor